Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601), a leading Chinese vaccine manufacturer, has entered into a strategic partnership with UK-based AstraZeneca (AZ, NASDAQ: AZN) and Indonesian pharmaceutical company Combiphar. The collaboration aims to strengthen the cooperation between China and Indonesia in the vaccine sector. Under the terms of the agreement, AstraZeneca and Combiphar will collaborate on the manufacturing and commercialization of Kangtai Bio’s vaccines, including its COVID-19 vaccine, in Indonesia. Financial details of the partnership have not been disclosed.
Kangtai Bio’s COVID-19 Vaccine and Exports to Indonesia
In 2021, Kangtai Bio took on the production of AstraZeneca’s adenovirus vector COVID-19 vaccine, initiating large-scale manufacturing in Shenzhen. The company successfully exported over 30 million doses of the vaccine to Indonesia, demonstrating its capability to meet international demand for COVID-19 vaccinations. This export milestone underscores Kangtai Bio’s role in global health initiatives and its commitment to combating the pandemic.
Global Cooperation for Pneumonia Vaccines
Beyond the COVID-19 vaccine, Kangtai Bio has also entered into cooperative promotion agreements with Indonesia, the Philippines, Pakistan, and other countries for its 13-valent and 23-valent pneumonia vaccines. These agreements highlight Kangtai Bio’s expanding global footprint in the vaccine industry and its dedication to improving public health through the distribution of life-saving vaccines.-Fineline Info & Tech
